Blueshift Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Blueshift Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,363	Closed	-$361K	–	501
2023 Q1	$361K	Buy	+3,363	New	+$387K	0.15%	191

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Blueshift Asset Management's RXDX Position: Q2 2023 in Review

Blueshift Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,363 shares — an estimated $361K sold.

Blueshift Asset Management first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $361K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Blueshift Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Blueshift Asset Management sold 3,363 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $361K.
Blueshift Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Blueshift Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $361K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Blueshift Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.